Losing The Battle Of The Bulge: FDA Holds Up Orexigen's Contrave
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Orexigen Therapeutics has a big decision on its hands – how to proceed with its Contrave program – now that FDA wants to see a large cardiovascular outcomes study before the drug can be considered for approval.